Mayo Clinic Identifies Mechanism for Breast Cancer Treatment Resistance

Mayo Clinic researchers have identified a crucial factor explaining why some HER2-positive breast cancers resist antibody-drug conjugates like trastuzumab deruxtecan. This discovery provides new insights into overcoming treatment resistance, potentially leading to improved therapeutic strategies and better outcomes for patients with these specific breast cancer types.